In last trading session, Fate Therapeutics Inc (NASDAQ:FATE) saw 2.16 million shares changing hands with its beta currently measuring 1.94. Company’s recent per share price level of $1.33 trading at -$0.04 or -2.92% at ring of the bell on the day assigns it a market valuation of $152.43M. That closing price of FATE’s stock is at a discount of -345.11% from its 52-week high price of $5.92 and is indicating a premium of 50.38% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.57 million shares which gives us an average trading volume of 2.32 million if we extend that period to 3-months.
For Fate Therapeutics Inc (FATE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.42. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Upright in the red during last session for losing -2.92%, in the last five days FATE remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $1.33 price level, adding 10.74% to its value on the day. Fate Therapeutics Inc’s shares saw a change of -19.39% in year-to-date performance and have moved 18.75% in past 5-day. Fate Therapeutics Inc (NASDAQ:FATE) showed a performance of 41.37% in past 30-days. Number of shares sold short was 16.37 million shares which calculate 7.52 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 66.75% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -125.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -125.56% for stock’s current value.
Fate Therapeutics Inc (FATE) estimates and forecasts
This year revenue growth is estimated to fall -66.32% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.18M for the same. And 9 analysts are in estimates of company making revenue of 1.18M in the next quarter. Company posted 1.93M and 6.77M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.63% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 7.36% while estimates for its earnings growth in next 5 years are of 7.78%.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
Insiders are in possession of 2.24% of company’s total shares while institution are holding 89.78 percent of that, with stock having share float percentage of 91.84%. Investors also watch the number of corporate investors in a company very closely, which is 89.78% institutions for Fate Therapeutics Inc that are currently holding shares of the company. REDMILE GROUP, LLC is the top institutional holder at FATE for having 13.17 million shares of worth $43.19 million. And as of 2024-06-30, it was holding 11.2107 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.998 of outstanding shares, having a total worth of $34.67 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.05 shares of worth $4.06 million or 2.66% of the total outstanding shares. The later fund manager was in possession of 2.62 shares on Mar 31, 2025 , making its stake of worth around $3.49 million in the company or a holder of 2.29% of company’s stock.
